Glycanostics
Financials
Estimates*
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | - | <1m | <1m | <1m | <1m | 1.4m |
| % growth | - | - | 13 % | 172 % | 333 % | 55 % |
| EBITDA | - | - | - | (<1m) | (<1m) | (<1m) |
| % EBITDA margin | - | - | - | (143 %) | (42 %) | (17 %) |
| Profit | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) | (<1m) |
| % profit margin | - | (16 %) | (10 %) | (144 %) | (49 %) | (20 %) |
| R&D budget | - | <1m | <1m | <1m | 1.3m | 1.7m |
| R&D % of revenue | - | 101 % | 103 % | 243 % | 146 % | 117 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
* | €50.0k | Grant | |
* | €310k | Seed | |
* | €2.0m | Grant | |
* | €690k | Seed | |
N/A | Early VC | ||
* | €2.5m | Grant | |
* | €1.6m | Early VC | |
* | €3.0m | Grant | |
| Total Funding | €10.1m | ||
Related Content
Recent News about Glycanostics
EditGlycanostics has developed highly accurate, early-stage tests for detection of 11 types of cancer. The tests are based on detection of glycan changes in blood using Magnetic-based-ELISA. Our solution represents a novel and unique approach, protected by 5 patents so far.
It has the following unique features:
It is minimally-invasive (it analyses glycans from blood serum); It detects early stage of the disease with high accuracy; It is fast and easy to work with; highly affordable; compatible with equipment already used by laboratories world-wide (ELISA), and suitable for large-scale screening; It is organ specific, and suitable for disease monitoring and active surveillance as it provides quantitative and qualitative information.
Our first product (prostate cancer test) is currently being launched in Europe, to be followed by breast cancer test later in 2025.
Keywords: Pharmaceuticals and Biotechnology, Analytical Chemistry, Assay Development Kits, Cancer Diagnostic Research, Cancer Diagnostic System, Cancer Diagnostic Test, Cancer Diagnostic Tools, Cancer Diagnostics Innovation.